Integra LifeSciences Announces Executive and Board Changes
Ticker: IART · Form: 8-K · Filed: Dec 12, 2025 · CIK: 917520
| Field | Detail |
|---|---|
| Company | Integra Lifesciences Holdings Corp (IART) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
TL;DR
Integra LifeSciences shakes up exec team and board on Dec 11, 2025.
AI Summary
Integra LifeSciences Holdings Corp. announced on December 11, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and the election of new directors, alongside updates to executive compensation arrangements.
Why It Matters
Changes in executive leadership and board composition can signal shifts in company strategy, operational focus, or financial direction.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Integra LifeSciences Holdings Corp. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- December 11, 2025 (date) — Date of earliest event reported
FAQ
What specific roles have seen departures or appointments?
The filing indicates departures of certain officers and the election of directors, but does not specify individual roles in this summary.
Are there any details on the new compensation arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but specific details are not provided in the summary.
When was the earliest event reported in this 8-K?
The earliest event reported was on December 11, 2025.
What is Integra LifeSciences Holdings Corp.'s primary business?
Integra LifeSciences Holdings Corp. is in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' industry.
What is the company's principal executive office address?
The principal executive offices are located at 1100 Campus Road, Princeton, NJ 08540.
Filing Stats: 987 words · 4 min read · ~3 pages · Grade level 14.8 · Accepted 2025-12-12 16:31:13
Filing Documents
- iart-20251211.htm (8-K) — 28KB
- exhibit101_cic2026.htm (EX-10.1) — 107KB
- 0000917520-25-000100.txt ( ) — 300KB
- iart-20251211.xsd (EX-101.SCH) — 2KB
- iart-20251211_def.xml (EX-101.DEF) — 14KB
- iart-20251211_lab.xml (EX-101.LAB) — 25KB
- iart-20251211_pre.xml (EX-101.PRE) — 15KB
- iart-20251211_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 10.1 Change in Control Severance Program 104 Cover Page Interactive Data File (embedded within the inline XRBL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTEGRA LIFESCIENCES HOLDINGS CORPORATION Date: December 12, 2025 By: /s/ Lesha Shinn Lesha Shinn Title: Vice President, Deputy General Counsel, Corporate and Business Development and Secretary